Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Beta Bionics (BBNX) Enterprise Value (2025 - 2026)

Beta Bionics' Enterprise Value history spans 4 years, with the latest figure at -$30.3 million for Q1 2026.

  • On a quarterly basis, Enterprise Value rose 86.91% to -$30.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$30.3 million, a 86.91% increase, with the full-year FY2025 number at -$219.1 million, down 111.56% from a year prior.
  • Enterprise Value hit -$30.3 million in Q1 2026 for Beta Bionics, up from -$219.1 million in the prior quarter.
  • Over the last five years, Enterprise Value for BBNX hit a ceiling of -$13.0 million in Q2 2024 and a floor of -$249.7 million in Q2 2025.
  • Historically, Enterprise Value has averaged -$121.2 million across 4 years, with a median of -$100.2 million in 2023.
  • Biggest five-year swings in Enterprise Value: plummeted 1816.65% in 2025 and later surged 86.91% in 2026.
  • Tracing BBNX's Enterprise Value over 4 years: stood at -$96.7 million in 2023, then decreased by 7.06% to -$103.6 million in 2024, then crashed by 111.56% to -$219.1 million in 2025, then surged by 86.17% to -$30.3 million in 2026.
  • Business Quant data shows Enterprise Value for BBNX at -$30.3 million in Q1 2026, -$219.1 million in Q4 2025, and -$228.7 million in Q3 2025.